In the pivotal Phase 3 trials of tesamorelin, adults with HIV-associated lipodystrophy who injected 2 mg daily lost between 10.9% and 15.4% of their visceral abdominal fat over 26 weeks, while placebo groups gained fat (Falutz et al., NEJM 2007; pooled Phase 3 analysis, JCEM 2010). A full year of continuous treatment deepened the reduction to roughly 17.5–18% (Falutz et al., AIDS 2008) — and the fat under the skin barely moved.
So what does tesamorelin do? It is a synthetic analog of growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone from outside, it signals the pituitary gland to release more of the body's own, in the pulsed rhythm the body already uses. The resulting rise in growth hormone and IGF-1 preferentially mobilizes visceral fat — the metabolically active fat packed around the liver, pancreas, and intestines. Below: the mechanism, the trial record, the label's side effects, and the regulatory fine print.
How tesamorelin works
Tesamorelin is a 44-amino-acid copy of human GHRH with one added chemical group. It binds GHRH receptors on the pituitary's somatotroph cells, prompting synthesis and pulsatile release of the body's own growth hormone; growth hormone in turn drives the liver to produce IGF-1, which carries out most downstream effects, including fat breakdown.
The added group — a trans-3-hexenoic acid (hexenoyl) moiety attached to the tyrosine at the peptide's amino end — protects tesamorelin from dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly degrades natural GHRH, extending its stability while preserving receptor binding (LiverTox, NCBI Bookshelf).
The broader frame for this mechanism: untreated growth hormone deficiency in adults produces a phenotype resembling metabolic syndrome — central adiposity, insulin resistance — which is why GHRH analogs draw research interest for body composition in the first place (Front Endocrinol 2021).
Routing the signal through the pituitary keeps the body's feedback loops intact: when IGF-1 rises, the pituitary eases off — a brake that injected growth hormone (somatropin) bypasses. Release also stays pulsatile, which is credited for a gentler metabolic profile than pharmacologic growth hormone, itself associated with hyperglycemia, insulin resistance, fluid retention, and carpal tunnel syndrome (review, HIV/AIDS (Auckland) 2011). In a two-week study of 13 healthy men, tesamorelin raised overnight growth hormone secretion and IGF-1 (+181 μg/L) without changing fasting glucose or insulin-stimulated glucose uptake (Stanley et al., JCEM 2011). Our sermorelin vs. HGH comparison walks through the stimulate-versus-replace trade-off in depth.
Why visceral fat in particular? Growth hormone promotes lipolysis — the breakdown of stored triglycerides into free fatty acids — and visceral adipose tissue is more metabolically active and more sensitive to that signal than the fat under the skin. It is also the depot most tied to cardiometabolic trouble, from atherosclerosis and hypertension to diabetes and dyslipidemia (Front Cardiovasc Med 2023; Commun Med 2025).
What does tesamorelin do in clinical trials?
Every major tesamorelin trial measured the same primary outcome — visceral adipose tissue (VAT) on CT scan — in adults with HIV, and the direction was consistent: visceral fat fell on treatment, rose on placebo, and subcutaneous fat stayed put.
| Trial | Year | N | Population | VAT result |
|---|---|---|---|---|
| Falutz et al., NEJM | 2007 | 412 | HIV, abdominal fat accumulation | −15.2% vs +5.0% on placebo (26 weeks) |
| Falutz et al., JAIDS | 2010 | 404 | HIV-associated lipodystrophy | −10.9% (−21 cm²) at 26 weeks; ~−18% at 12 months |
| Falutz et al., JCEM, pooled Phase 3 | 2010 | 806 | HIV-associated lipodystrophy | −15.4% effect at week 26; −17.5% (−35 cm²) at week 52 |
| Stanley et al., JAMA | 2014 | 50 | HIV, abdominal fat | −34 cm² vs +8 cm² at 6 months (P = .005) |
| Stanley et al., Lancet HIV | 2019 | 61 | HIV + NAFLD | Liver fat −4.1% absolute; 35% vs 4% normalized |
| Badran et al., meta-analysis | 2026 | 5 RCTs | HIV populations | −27.71 cm² vs placebo |
The NEJM trial — the largest single study, with 412 participants — also recorded triglycerides falling 50 mg/dL on tesamorelin versus rising 9 mg/dL on placebo, alongside an 81% rise in IGF-1. The pooled analysis of 806 participants confirmed the selectivity directly: visceral fat fell 24 cm² by week 26 while subcutaneous fat was statistically unchanged. In the secondary literature, a visceral-fat reduction of at least 8% marks a clinical response, and roughly 70% of treated participants met it (Lake et al., AIDS 2021). The JAMA trial added the liver directly: liver fat fell 2.0% on tesamorelin versus a 0.9% rise on placebo, a net difference of 2.9 percentage points (P = .003). The pooled phase 3 analysis also recorded improved body-image distress alongside the fat changes — a patient-reported outcome, not just an imaging one. The 2026 meta-analysis in Obesity Research & Clinical Practice adds the whole-body picture: trunk fat down 1.18 kg, liver fat down 4.28%, waist down 1.61 cm — and lean body mass up 1.42 kg, with no significant change in subcutaneous fat or BMI.
The findings extend past fat quantity. In responder analyses of the Phase 3 trials, trunk muscle density improved in all four muscle groups measured and the rectus and psoas muscles gained area (Adrian et al., J Frailty & Aging 2019); remaining fat became denser — a marker of smaller, healthier fat cells (Lake et al., above). In the 12-month liver trial, 35% of treated participants versus 4% on placebo brought liver fat below the 5% threshold that defines fatty liver (Stanley et al., Lancet HIV 2019, above), and a 2024 secondary analysis found the visceral-fat effect holds on modern integrase-inhibitor HIV regimens (Russo et al., AIDS 2024).
Two boundaries frame this. These trials enrolled adults with HIV, most with lipodystrophy from long-term antiretroviral therapy — the results do not automatically generalize to anyone else. And findings outside the fat story are mixed: a 20-week randomized trial in 152 older adults without HIV, at a lower 1 mg dose, reported favorable effects on executive function (Baker et al., Archives of Neurology 2012), while a 2025 open-label study in 73 people with HIV found no significant cognitive difference versus standard care (Ellis et al., Journal of Infectious Diseases 2025).
What happens when you stop
The benefits last only as long as the treatment. In the 52-week extension of the pivotal program, participants re-randomized from tesamorelin to placebo saw visceral fat reaccumulate, with improvements rapidly lost after the switch (Falutz et al., AIDS 2008; Falutz et al., JAIDS 2010). Tesamorelin changes hormonal signaling while it is present; it does not appear to reset how the body stores fat. In practice that makes it a maintenance therapy, not a short course with a lasting endpoint.
Tesamorelin alone or in combination
Prescribers sometimes pair a GHRH analog with a peptide that stimulates growth hormone through a different receptor. Ipamorelin belongs to the growth hormone-releasing peptide (GHRP) class, and in an early study in healthy men, a GHRP given with GHRH released more growth hormone than either signal alone (GH-releasing peptide study, 1990). Whether a combination fits — and which one — is an individualized prescribing decision, not a default upgrade. For background, see our guide to CJC-1295 and ipamorelin and the wider hormone & organ health catalog.
Tesamorelin's FDA status
The regulatory story has two halves. The branded product, Egrifta, earned FDA approval in November 2010 — not for weight loss, but for a single indication: "reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." An updated formulation, EGRIFTA WR — still a daily injection at 1.28 mg, but reconstituted weekly rather than daily — was FDA-approved on March 25, 2025, for that same indication.
The label is blunt about limits: Egrifta is not indicated for weight loss, and long-term cardiovascular safety has not been established. Tesamorelin also has not been approved for anti-aging, athletic performance, cognitive enhancement, or general metabolic health in people without HIV.
Promise dispenses tesamorelin as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded drugs are prepared by licensed pharmacies for an individual patient under a prescription — legal to prescribe, but outside FDA's premarket review. A licensed provider may still prescribe compounded tesamorelin where they judge it clinically appropriate — that decision is between you and your doctor.
Side effects and safety
The most common side effects on tesamorelin's label are joint pain (arthralgia, about 13%), injection-site redness (about 8.5%), muscle aches, fluid retention with swelling in the hands or feet, headache, and tingling (paresthesia). The safety record comes from adults with HIV-associated lipodystrophy studied for 26 to 52 weeks, where overall adverse-event rates did not differ significantly from placebo, though more treated participants withdrew for side effects.
Glucose runs in both directions. On the label, HbA1c reached 6.5% or higher in 5% of treated participants versus 1% on placebo by week 26 — a hazard ratio of 3.3 (confidence interval 1.4–9.6) — and in the JAMA trial, fasting glucose rose about 9 mg/dL in the first two weeks before showing no significant difference at six months. Yet a 12-week randomized trial in 53 patients with type 2 diabetes found no significant change in fasting glucose, HbA1c, or diabetes control (Clemmons et al., PLoS One 2017), and the 2026 meta-analysis reported no glucose perturbation across trials. The label's instruction: evaluate glucose before starting and monitor periodically.
Rarer risks: hypersensitivity reactions occurred in roughly 3.6% of treated patients, and anti-tesamorelin antibodies can develop, some cross-reacting with natural GHRH. Because growth hormone and IGF-1 could in theory stimulate an existing malignancy — and lifetime animal carcinogenicity studies were not conducted — active cancer is a contraindication, alongside disruption of the hypothalamic–pituitary axis (pituitary tumors or surgery, head irradiation, or trauma), known hypersensitivity, and pregnancy. Trials showed no significant liver-toxicity signal (LiverTox); prescribers typically monitor glucose, HbA1c, and IGF-1 during use.
What to weigh before a tesamorelin consult
Four things worth settling first:
- Match the evidence to your situation. The headline numbers come from adults with HIV-associated lipodystrophy; if that isn't you, the strongest data were generated in a different population — worth raising directly with a provider.
- Plan for maintenance. Visceral fat reaccumulated when trial participants stopped. Tesamorelin is a daily injection for as long as the benefit is wanted, not a finite course.
- Budget for monitoring. Glucose and HbA1c checks are part of responsible use, and IGF-1 is typically tracked; a personal or family history of diabetes belongs in your intake answers.
- Know the exclusions. Pregnancy, active cancer, and pituitary-axis conditions rule tesamorelin out — the contraindication list is much of the reason a clinician sits between you and the medication.
Through Promise, every tesamorelin request is reviewed by a licensed provider who takes a full health history — not everyone qualifies, and the provider may decline. The medication itself is a compounded prescription prepared by a licensed U.S. compounding pharmacy.
This article is for educational purposes and is not medical advice. Talk with a licensed healthcare provider about your health, medications, and goals before starting, stopping, or combining any prescription therapy.